Physician profile
Roberto Rodriguez
NPI 1821069550
$7,026.36
in general payments reported to CMS, 2019-2025
28 companies · $1,768 in 2025
The $1,768 reported for 2025 was more than what a typical Allergy provider received nationally (typical 2025 total: $1,129).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $684 · 2020: $118 · 2021: $169 · 2022: $1,478 · 2023: $1,662 · 2024: $1,148 · 2025: $1,768.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $4,578.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $4,577.88 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Astrazeneca Pharmaceuticals LP | $1,477.15 | 2019-2025 | Tezspire, Airsupra, Fasenra |
| Glaxosmithkline, LLC. | $1,252.92 | 2019-2025 | Arexvy, Nucala, Trelegy Ellipta |
| Genzyme Corporation | $1,008.76 | 2022-2025 | |
| Amgen INC. | $448.19 | 2021-2023 | |
| Sanofi-Aventis U.S. LLC | $371.31 | 2022-2023 | |
| Genentech USA, INC. | $337.80 | 2019-2025 | Xolair |
| Pfizer INC. | $320.83 | 2019-2023 | |
| Shire North American Group INC | $247.07 | 2019 | |
| Grifols USA, LLC | $193.36 | 2024-2025 | Xembify |
| Alk-Abello, INC | $172.91 | 2019-2023 | Grastek, Odactra, Ragwitek |
| Abbvie INC. | $123.65 | 2022 | |
| Blueprint Medicines Corporation | $121.49 | 2025 | Ayvakit |
| Lilly USA, LLC | $118.26 | 2025 | Ebglyss |
| Novartis Pharmaceuticals Corporation | $116.60 | 2025 | |
| Ars Pharmaceuticals Operations, INC. | $112.13 | 2025 | Neffy |
Show all 28 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Adma Biomanufacturing LLC | $90.76 | 2025 | |
| Covis Pharma Gmbh | $89.11 | 2021-2023 | |
| Orthofix Medical, INC. | $83.99 | 2025 | Physio-Stim |
| Regeneron Healthcare Solutions, INC. | $77.72 | 2022-2024 | Dupixent |
| Kaleo, INC. | $44.64 | 2024 | Auvi-Q |
| Stryker Corporation | $44.60 | 2025 | Augment Injectable |
| Abiomed | $41.47 | 2025 | |
| Optinose US, INC. | $40.27 | 2019-2022 | |
| Uswm, LLC | $22.00 | 2021 | |
| Teva Pharmaceuticals USA, INC. | $21.74 | 2022 | |
| Biohaven Pharmaceutical Holding Company LTD. | $21.47 | 2022 | |
| Mylan Pharmaceuticals INC. | $13.81 | 2019 | |
| Sunovion Pharmaceuticals INC. | $12.35 | 2020 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Roberto Rodriguez listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.